DURECT Receives Orphan Drug Designation for Bupivacaine for Post-Herpetic Neuralgia
CUPERTINO, Calif., June 30 /PRNewswire-FirstCall/ — Durect Corporation announced today that the US Food and Drug Administration (FDA) has granted to Durect orphan drug designation for bupivacaine for relief of persistent pain associated with post-herpetic neuralgia (PHN). Bupivacaine is the active pharmaceutical ingredient in Eladur(TM), Durect’s investigational transdermal drug patch. If Eladur is the first bupivacaine product approved for PHN, under the 1983 Orphan Drug Act Eladur will receive seven years of market exclusivity following the approval of the product by the FDA.
Eladur is an …read more